Bevacizumab for optic pathway glioma with worsening visual field in absence of imaging progression: 2 case reports and literature review

Childs Nerv Syst. 2020 Mar;36(3):635-639. doi: 10.1007/s00381-019-04407-6. Epub 2019 Nov 7.

Abstract

Children with optic pathway gliomas (OPGs) frequently suffer from problems of visual function resulting from tumors. Previous reports showed that bevacizumab improved visual function in patients with OPG via tumor response to treatment. In these two case reports, we show that bevacizumab improved visual field without tumor response as seen in imaging. Both, a 10-year-old girl and a 6-year-old boy, had previous history of treatment with platinum-based chemotherapy. They had visual deterioration without tumor progression on MR imaging. Bevacizumab effectively and immediately improved visual field in both patients without imaging response of OPG. We emphasize that bevacizumab should be considered for patients with OPGs having visual deterioration without tumor progression.

Keywords: Bevacizumab; Optic pathway glioma; Visual field.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Bevacizumab / therapeutic use
  • Child
  • Female
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Neurofibromatosis 1*
  • Optic Nerve Glioma* / diagnostic imaging
  • Optic Nerve Glioma* / drug therapy
  • Retrospective Studies
  • Vision, Ocular
  • Visual Fields

Substances

  • Bevacizumab